Medivir Q1: Revenue Rises, Loss Narrows, Funds New Trials

Key Financials and Strategic Funding

Swedish drug developer Medivir announced improved first-quarter financial results, reporting higher revenue and a reduced EBITDA loss. The company also successfully completed a directed share issue to secure funding for its ongoing clinical development programs.

Q1 Performance Overview

For the first quarter, Medivir posted revenue of SEK 1 million. The company's EBITDA loss narrowed significantly to SEK 8.80 million, indicating improved operational efficiency. Adjusted free cash flow for the period was negative SEK 13 million. The firm's financial position was strengthened, with cash and cash equivalents rising to SEK 149.1 million by the end of the quarter.

Impact and Future Outlook

A key development in the quarter was the completion of a SEK 45 million directed share issue in February. CEO Jens Lindberg stated this capital strengthens the company’s finances and is crucial for advancing its drug candidates. Medivir plans to initiate a phase 2 proof-of-concept study for MIV-711 in Osteogenesis Imperfecta and will begin a randomized study of fostrox for second-line liver cancer. Additionally, results from a veterinary study for MIV-701 are anticipated in the fourth quarter of 2026.

Summary

Medivir's first quarter shows positive momentum with a stronger balance sheet and a narrower loss. The new funding is pivotal, enabling the company to advance its key clinical trials for MIV-711 and fostrox, which will be critical milestones for investors to monitor.

FAQ

Q: What were Medivir's key financial results for the first quarter?
A: Medivir reported revenue of SEK 1 million, a narrowed EBITDA loss of SEK 8.80 million, and an increase in cash reserves to SEK 149.1 million.

Q: How will Medivir use the funds from its recent share issue?
A: The SEK 45 million raised will primarily fund the clinical development of MIV-711 for Osteogenesis Imperfecta and a study of fostrox for liver cancer.

Source: Investing.com